Apotheken
|
Doctor
|
Drugs
|
Hospital
|
Interactions
|
MiGeL
|
Registration owner
|
Services
Home
<
List for "H01CB" (30)
–
Sort according to Concentration, Size and Price
Price comparison
Price comparison and Component
Brand name
Component
Registration owner
Indication
Interaction
Unwanted Effect
Swissmedic-# (5-digit)
Pharmacode
Product
Package Size
EFP
CP
SB
DC
Composition
Registr. Holder
Category
Somatostatin (H01CB01) 2 products
WHO-DDD
DrugBank.ca
IP
CI
Stilamin 3 mg
PR
PR
k.A.
Lyophilisate: Somatostatinum 3 mg
Hasten
Biopharmaceutic
(Switzerland) AG
A
FB
G
IP
CI
Stilamin 3 mg
ampoule(s)
PR
PR
k.A.
Lyophilisate: Somatostatinum 3 mg
Hasten
Biopharmaceutic
(Switzerland) AG
A
FB
G
Octreotide (H01CB02) 17 products
WHO-DDD
DrugBank.ca
L
IP
CI
Sandostatin 0,05 mg/mL
5 1 ampoule(s) à 1 ml
22.19
40.40
10 %
Injection solution: Octreotidum
Novartis Pharma
Schweiz AG
A / SL / SO
FB
G
L
IP
CI
Sandostatin 0,1 mg/mL
5 1 ampoule(s) à 1 ml
41.38
61.15
10 %
Injection solution: Octreotidum
Novartis Pharma
Schweiz AG
A / SL / SO
FB
G
L
IP
CI
Sandostatin 0,5 mg/mL
5 1 ampoule(s) à 1 ml
227.65
262.60
10 %
Injection solution: Octreotidum
Novartis Pharma
Schweiz AG
A / SL / SO
FB
G
L
IP
CI
Sandostatin LAR 10 mg
Fertigspritzen
10 mg
505.79
560.55
10 %
Injection preparation: Octreotidum 10 mg
Novartis Pharma
Schweiz AG
A / SL / SO
FB
G
L
IP
CI
Sandostatin LAR 20 mg
Fertigspritzen
20 mg
897.90
982.40
10 %
Injection preparation: Octreotidum 20 mg
Novartis Pharma
Schweiz AG
A / SL / SO
FB
G
L
IP
CI
Sandostatin LAR 30 mg
Fertigspritzen
30 mg
1265.46
1377.85
10 %
Injection preparation: Octreotidum 30 mg
Novartis Pharma
Schweiz AG
A / SL / SO
FB
G
L
IP
Octreotid Labatec 0,05
mg/mL
5 1 ampoule(s) à 1 ml
19.99
38.15
10 %
Solution pour injection: Octreotidum
Labatec Pharma SA
A / SL / SG
FB
G
L
IP
Octreotid Labatec 0,1
mg/mL
5 1 ampoule(s) à 1 ml
37.24
56.90
10 %
Solution pour injection: Octreotidum
Labatec Pharma SA
A / SL / SG
FB
G
L
IP
Octreotid Labatec 0.2
mg/ml
Durchstechflasche(n) à 5 ml
69.54
92.05
10 %
Solution pour injection: Octreotidum 1mg / 5ml
Labatec Pharma SA
A / SL / SG
FB
G
L
IP
Octreotid Labatec 0,5
mg/mL
5 1 ampoule(s) à 1 ml
204.98
239.35
10 %
Solution pour injection: Octreotidum
Labatec Pharma SA
A / SL / SG
FB
G
IP
Octreotid-Teva 0.05 mg/ml
Durchstechflasche(n)
PR
PR
k.A.
Injektionslösung oder Konzentrat zur Herstellung einer Infusionslösung: Octreotidum
Teva Pharma AG
A
FB
G
IP
Octreotid-Teva 0.05 mg/ml
5 Durchstechflasche(n)
PR
PR
k.A.
Injektionslösung oder Konzentrat zur Herstellung einer Infusionslösung: Octreotidum
Teva Pharma AG
A
FB
G
IP
Octreotid-Teva 0.1 mg/ml
Durchstechflasche(n)
PR
PR
k.A.
Injektionslösung oder Konzentrat zur Herstellung einer Infusionslösung: Octreotidum
Teva Pharma AG
A
FB
G
IP
Octreotid-Teva 0.1 mg/ml
5 Durchstechflasche(n)
PR
PR
k.A.
Injektionslösung oder Konzentrat zur Herstellung einer Infusionslösung: Octreotidum
Teva Pharma AG
A
FB
G
IP
Octreotid-Teva 0.2 mg/ml
Durchstechflasche(n)
PR
PR
k.A.
Injektionslösung oder Konzentrat zur Herstellung einer Infusionslösung: Octreotidum
Teva Pharma AG
A
FB
G
IP
Octreotid-Teva 0.5 mg/ml
Durchstechflasche(n)
PR
PR
k.A.
Injektionslösung oder Konzentrat zur Herstellung einer Infusionslösung: Octreotidum
Teva Pharma AG
A
FB
G
IP
Octreotid-Teva 0.5 mg/ml
5 Durchstechflasche(n)
PR
PR
k.A.
Injektionslösung oder Konzentrat zur Herstellung einer Infusionslösung: Octreotidum
Teva Pharma AG
A
FB
G
Lanreotide (H01CB03) 3 products
WHO-DDD
DrugBank.ca
L
IP
CI
Somatuline Autogel 60 mg
725.83
805.80
10 %
Injection solution: Lanreotidum 60 mg
Ipsen Pharma Schweiz
GmbH
A / SL
FB
G
L
IP
CI
Somatuline Autogel 90 mg
1001.92
1106.05
10 %
Injection solution: Lanreotidum 90 mg
Ipsen Pharma Schweiz
GmbH
A / SL
FB
G
L
IP
CI
Somatuline Autogel 120 mg
1290.70
1420.15
10 %
Injection solution: Lanreotidum 120 mg
Ipsen Pharma Schweiz
GmbH
A / SL
FB
G
Pasireotide (H01CB05) 8 products
WHO-DDD
DrugBank.ca
L
IP
CI
PP
Signifor 0.3 mg/1 ml
30 ampoule(s)
2013.84
2206.60
10 %
Injection solution: Pasireotidum
Recordati AG
B / SL
FB
G
L
IP
CI
PP
Signifor 0.6 mg/1 ml
30 ampoule(s)
2013.84
2206.60
10 %
Injection solution: Pasireotidum
Recordati AG
B / SL
FB
G
L
IP
CI
PP
Signifor 0.9 mg/1 ml
30 ampoule(s)
2013.84
2206.60
10 %
Injection solution: Pasireotidum
Recordati AG
B / SL
FB
G
L
IP
CI
PP
Signifor LAR 20 mg
Durchstechflasche(n) à 20 mg
3011.01
3291.05
10 %
Pulver und Lösung zur Herstellung einer Injektionssuspension: Pasireotidum 20 mg
Recordati AG
A / SL
FB
G
L
IP
CI
PP
Signifor LAR 40 mg
Durchstechflasche(n) à 40 mg
3011.01
3291.05
10 %
Pulver und Lösung zur Herstellung einer Injektionssuspension: Pasireotidum 40 mg
Recordati AG
A / SL
FB
G
L
IP
CI
PP
Signifor LAR 60 mg
Durchstechflasche(n) à 60 mg
3011.01
3291.05
10 %
Pulver und Lösung zur Herstellung einer Injektionssuspension: Pasireotidum 60 mg
Recordati AG
A / SL
FB
G
IP
PP
Signifor LAR 10 mg
10 mg
PR
PR
k.A.
Pulver und Lösung zur Herstellung einer Injektionssuspension: Pasireotidum 10 mg
Recordati AG
A
FB
G
IP
PP
Signifor LAR 30 mg
30 mg
PR
PR
k.A.
Pulver und Lösung zur Herstellung einer Injektionssuspension: Pasireotidum 30 mg
Recordati AG
A
FB
G
show caption
Red = Original
CM
= Co-Marketing
EFP = Ex-Factory-Price, exkl. VAT CHF
Green = Generic Drug
V/S
= vaccine/blood product
CP = Consumer Price, inkl. VAT CHF
Black = not classified
A
= Anesthetic
PR = Price request
Gray background = Pending Permission Extension
SIP
= Short Information for Professionals
SB = Selbstbehalt
H
= Homeopathics
IP
= Information for Professionals
DC = Daily Cost
A
= Anthroposophics
CI
= Consumer Information
SL = Official reimbursement list of Switzerland.
Ph
= Phytotherapeutics
L
= Limitations
SO = Original according to SL
Cas Reg.Nr. = CAS Registry
G
= Google Search by Product Name
SG = Generic according to SL
P
= Import parallel
FB
= Drugs Feedback
LPPA = Liste des produits pharmaceutiques pour application spéciale
Legal Disclaimer
ATC-Browser
|
Drugs A-Z
|
Recent Registrations
2025
©ywesee GmbH
Settings
|
Help
|
FAQ
|
Login
|
Contact
|
Home
